

**REMARKS**

The applicant has amended claims 1 and 4 to exclude the compound of Katsushima *et al.*, thereby out the aiding the 102(b) rejection. Claim 7 has not been amended in this manner because Katsushima does not disclose the claimed method.


Claims 3, 6, and 9 have been amended to remove the 6<sup>th</sup> through 8<sup>th</sup> compounds, thereby obviating the § 112 rejection based on these compounds. This canceled subject matter has been moved to new claims 12-15.

Claim 7 has been further amended to clarify that it is directed to a method of treating congestive heart failure.

In view of the foregoing amendments and remarks, the applicant submits that the claims are in condition for allowance, which is respectfully solicited. If the examiner believes a teleconference will advance prosecution, he is encouraged to contact the undersigned as indicated below.

Date: February 14, 2005

Respectfully submitted,

  
Michael S. Greenfield  
Registration No. 37,142

Telephone: 312-913-0001  
Facsimile: 312-913-0002

**McDonnell Boehnen Hulbert & Berghoff LLP**  
300 South Wacker Drive  
Chicago, IL 60606